EFFICACY AND SAFETY OF SGLT2i IN THE ELDERLY WITH CKD

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/57925cf0226ccb9f623e3331dc056e23.pdf

Abstract Title *

EFFICACY AND SAFETY OF SGLT2i IN THE ELDERLY WITH CKD

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Vjollca Godanci Kelmendi vjollcagodanci@gmail.com UCCK Nephrology Prishtina Kosovo *

Co-author 2

Mimoza Ramadani Piraj mimoza.ramadanipiraj@gmail.com Asklepi Med Endocrinology Prishtina Kosovo -

Co-author 3

Shega Konjufca shegakonjufca@gmail.com Asklepi Med Nephrology Prishtina Kosovo -

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

SGLT2 (Sodium-Glucose Cotransporter 2) inhibitors have attracted the attention of clinicians in the fields of nephrology, endocrinology, cardiology, etc.

These drugs have demonstrated not only high effectiveness in the treatment of DN, but also in other chronic kidney diseases with proteinuria, regardless of the cause.

Methods

Descriptive and comparative prospective cohort study. 50 T2D patients with ND treated with empagliflozin, compared with a control group of 50 diabetic patients with ND treated with ACE/ARB and other glucose-lowering agents. 25 non-diabetic patients treated with SGLT2i for glomerular disease were also included in this study.

Results

The results of our study showed a significant improvement in the group of patients with type 2 diabetes (T2D) treated with SGLT2i. (see tables 1, 2 and 3)

In the group of 68 patients over the age of 65 treated with SGLT2i, specific changes and results were observed (tab 4) on In addition, the frequency of dehydration, hydroelectrolytic disorders, as well as cases of falls, fractures and amputations were monitored to evaluate the safety of treatment in the elderly population.

50 pt	T2D SGLT2i	50 pt	T2D Control Group	20 PT sGLT2i	CKD No T2D
Ur Prot 24	- 811 mg/ 24 h ▼	Ur Prot 24	- 121 mg/24 h▼	Ur Prot 24	- 690 mg/gl ▼
eGFR MDRD	+ 15.44 ml/min ▲	eGFR MDRD	- 3.3 ml/min ▼	eGFR MDRD	+14.4 ml/min ▼
HbA1c	- 1.41 % ▼	HbA1c	- 1.45 % ▼	HbA1c
Chol	- 1.11 mmol/l ▼	Chol	- 0.3 mmol/l ▼	Chol	- 0.9 mmol/l ▼
BMI	- 0.9 kg/m2 ▼	BMI	+ 0.8 kg/m2▲	BMI	- 0.3 kg/m 2▲

Stratification of the sample for patients over 65 years old

68 PT sGLT2i >65 yrs	CKD
SBP	- 10 mmHg ▼
DBP	- 0.8 mmHg ▼
Sodium	- 1.4 mmol/l; ▼
HbA1C	- 1.47 mmol/l ▼
BMI	- 1.2 kg/m 2 ▼

Conclusion

Our results suggest that SGLT2i treatment is a safe and effective modality for DN and CKD diseases with proteinuria, regardless of cause.

In patients over 65 years of age the benefits of treatment were evident, SGLT2i were well tolerated and proved safe for the elderly, with special care for the most frail subjects.

Kewords